Abstract: A pharmaceutical composition for use in the treatment of the symptoms of an addiction is disclosed. The pharmaceutical composition contains, but is not limited to, digestive enzymes. The pharmaceutical composition may further contain a coating that surrounds a core of digestive enzymes in the form of coated particles. The pharmaceutical composition may also be encapsulated. The therapeutic agent may be manufactured by a variety of technologies.

Abstract: An encapsulated composition for converting ethanol to acetaldehyde and subsequently converting the acetaldehyde to acetate. The composition includes alcohol dehydrogenase and aldehyde dehydrogenase in a molar ratio of approximately 1:3 to approximately 1:51. The composition is encapsulated by a polysaccharide-whey-casein encapsulant such that the encapsulated composition has a controlled release property in the small intestine. The composition reduces symptoms caused by over-consumption of alcohol.

Abstract: The invention relates to a fusion protein containing a selective cell death-inducing enzyme system for use in the therapy and/or treatment of cancer and tumors in humans and animals, a process, and its use.

Abstract: Pharmaceutical compositions comprising at least one lipid-based particle encapsulating a proteolytic enzyme and a pharmaceutically acceptable carrier, wherein the proteolytic enzyme comprises at least 75% proteolytically active enzyme are provided. Methods of using same and producing same are also provided.

Abstract: The invention concerns the improvement of metabolic and digestive health of humans by providing diagnostic methods for enterometabolic disorders such as IBS and IBD and/or the treatment of IBS and IBD by compositions comprising enzyme rich malt extract (ERME).

Abstract: The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of Lactobacilli species, 5 that when delivered to the bronchi or lungs of a patient can provide a reduction in the symptoms of a bronchopulmonary disease.

Abstract: The present invention relates to chimeric endolysin Lys109 which effectively controls Staphylococcus aureus, wherein the endolysin Lys109 of the present invention has a novel amino acid sequence that has not been conventionally studied. Endolysin Lys109 of the present invention can be used as a biological regulator capable of effectively inhibiting a wide range of Staphylococcus aureus and a biofilm produced thereby. In addition, endolysin Lys109 can kill Staphylococcus aureus without regard for resistance to conventional antibiotics, and thus can be widely used for treatment of diseases caused by Staphylococcus aureus infection. Moreover, endolysin Lys109 can also be used to resolve medical problems caused by Staphylococcus aureus which has antibiotic resistance.

Abstract: Methods and compositions for rejuvenating skeletal muscle stem cells are disclosed.

Abstract: A composition containing enzymes, L-arginine, and other components for treating exocrine pancreatic enzyme insufficiencies and gastrointestinal disorders in mammals. The compositions replace pancreatic enzymes while concurrently treating the side effects of small intestinal bacterial overgrowth and gastrointestinal mucosal degeneration that occurs with pancreatic enzyme loss. The composition can be mixed into animal feeds or sprayed onto extruded feeds prior to consumption.

Abstract: Bioactive coatings suitable for facilitating removal of a fingerprint when contacting the coating are provided including a base associated with a chemically modified enzyme, and, optionally a first polyoxyethylene present in the base and independent of the enzyme. The coatings are optionally overlayered onto a substrate. Also provided are processes of facilitating fingerprint removal.

Abstract: The present invention relates to the fields of collagenase production and collagenase products, and particularly to improving the reproducibility, purity, and stability of collagenase I and collagenase II compositions, where the compositions are pure to at least 95% by area as measured by reverse phase high pressure liquid chromatography (RP-HPLC) and essentially free of neutral protease.

Abstract: The present invention relates to an orodispersible tablet characterized in that it includes burlulipase. It also relates to liquid pharmaceutical compositions that contain solutions of such orodispersible tablets in water or other beverages. It relates to drugs that contain or consist of such orodispersible tablets or solutions. In particular, it relates to such drugs that are suitable for treating digestive problems, in particular exocrine pancreatic insufficiency used to treat digestive problems. In particular, they are for the treatment of exocrine pancreatic insufficiency in cystic fibrosis patients and for treatment of exocrine pancreatic insufficiency in pediatric patients.

Abstract: The invention provides an in vitro method for the determination of sun protection factor (SPF), in order to gain reproducibility and accuracy and replace the use of tests on living beings. Natural substrates of the human skin, like hyaluronic acid are tested in the form of solutions or in the form of a solid film in a modified spectrophotometer, at concentrations below 1% w/v. Once calibrated, the method is used to corroborate the protection factor offered by commercial sunscreens.

Abstract: The present invention is directed to a method for identifying ductal leaks during pancreobiliary surgery in a human patient. The invention comprises the steps of: administering to a human patient undergoing pancreobiliary surgery an effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier; and observing the patient during the surgery for the presence of pancreobiliary ductal leaks.

Abstract: The present invention relates to compositions, methods, uses and kits for treating cancer. The present invention relates to methods for minimising the progression of cancer in a subject, the method comprising administering to the subject therapeutically effective amounts of chymotrypsinogen and trypsinogen, thereby minimising the progression of cancer in the subject. In particular, the methods provide a means for treating cancer by reducing the number of cancer stem cells in the subject.

Abstract: Multispecific molecules that include i) a tumor-targeting moiety; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule; and/or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Abstract: Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least 10%, of the normal plasminogen activity and for maintaining the plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency.

Abstract: Detergent compositions that include a lipase variant of a parent lipase which has lipase activity and includes one or more substitutions corresponding to G23S, D27N, A40, F51I,L, E56R, D57N, V60E,K, K98I, N101D, R118, G163S, T231R, N233R, Y220F, T244E, and P256T using SEQ ID NO: 2 for numbering. Water-soluble unit dose articles including water-soluble film and a detergent composition including lipase variants. Methods of cleaning and/or treatment of surfaces using such compositions.

Abstract: Described herein are compositions and methods for the treatment and prevention of cognitive decline in subjects. Generally, among other potential components, the compositions comprise Centella asiatica or an extract thereof; ?-tocopherol or a derivative thereof; Ginseng or an extract thereof; a selenium compound, and ?-lipoic acid. Also provided are methods of making such compositions.

Abstract: The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of Lactobacilli species, 5 that when delivered to the bronchi or lungs of a patient can provide a reduction in the symptoms of a bronchopulmonary disease.

Abstract: In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises free asenapine, a maleic acid alkali salt, and a rubber-based adhesive agent.

Abstract: A method of preventing post-operative endophthalmitis involves injecting a colored antibiotic solution into the anterior segment of the eye during surgery, the antibiotic solution having moxifloxacin, cefuroxime, vancomycin, or some combination thereof, and the coloring agent being preferably a cobalamin (e.g., cyanocobalamin).

Abstract: The present invention relates to methods to improve the absolute rate of homology-directed repair (HDR) and/or to improve the relative rate of HDR compared with non-homologous end joining (NHEJ).

Abstract: The present invention is a resin composition including: a resin component; zinc oxide; and an acetic acid remover, wherein the resin component includes an ethylene-vinylacetate copolymer and a content of the ethylene-vinylacetate copolymer in the resin component is greater than or equal to 10% by mass, wherein the acetic acid remover is an acid acceptor, a nitrogen-containing aromatic heterocyclic compound having a mercapto group, or a combination thereof, and wherein a mass ratio of the zinc oxide to the ethylene-vinylacetate copolymer is greater than or equal to 0.06 and less than or equal to 0.20.

Abstract: Disclosed herein are nutraceutical compositions comprising or consisting essentially of one or more types of polyphenols (e.g., a green tea polyphenol) and one or more types of reactive oxygen species, and methods for their use to treat gastrointestinal conditions, inflammatory conditions, and immune conditions.

Abstract: The present invention discloses a composition for the therapeutic management of male sexual dysfunction and related disorders. Specifically, the invention discloses a composition comprising 60-65% w/w Withania somnifera extract, 12-18% w/w Mucana pruriens extract, 5-10% w/w Coleus forskolii extract, 12-18% w/w Kaempferia parviflora extract, 0.1-2% w/w Piper nigrum extract, for use as an aphrodisiac.

Abstract: A method of treating hypercholesterolemia in mammals, by administering an effective amount of a microbial fermentation product, and regulating genes involved in lipoprotein metabolism. A method of regulating cholesterol levels in a patient by administering an effective amount of a composition chosen from the group consisting of PAZ, specific components isolated from PAZ, chemically synthesized analogues of the components of PAZ, and regulating genes involved in lipoprotein metabolism. A method of treating high cholesterol levels in an individual by administering an effective amount of a microbial fermentation product, up-regulating the expression of at least one of the genes that encode ABCA1, ApoA1, and SRB1, and down-regulating the gene that encodes CETP. A method of preventing the onset of high cholesterol levels and/or a deleterious lipoprotein profile in an individual.

Abstract: Compositions and methods for treating or preventing S. aureus infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce S. aureus populations and thereby treat or prevent infection by S. aureus. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.

Abstract: The present disclosure is a compound, a method of making the compound and method of using such compound preferably in the form of a dietary supplement that, when administered, is capable of supporting memory, focus, and clarity. The unique combination of the composition is preferably administered orally. The composition is preferably comprised of at least Hericium Erinaceus, Bacopa Monnieri, ECGC (Epigallocatechin-3-Gallate), Huperzine, Acetyl-L-Carnitine, Vitamin B12, Ginkgo Biloba, Phosphatidylserine, and Gotu Kola, in pre-determined amounts. The composition can further comprise a palliative agent, and can be provided in the form of a capsule, powder, liquid or tablet.

Abstract: Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) and/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human ?-globin locus; (d) to disrupt a HbF silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbF silencing region; (e) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; (f) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; and/or (g) to correct one or more ?-globin gene mutation(s).

Abstract: Compositions containing bromelain are disclosed for use as topical therapeutic agents for the treatment of rosacea. The compositions include lotions, creams and ointments.

Abstract: Techniques for optimizing a magnetic resonance imaging (MRI) protocols are described herein. An example method can include receiving one or more MRI scanner settings for an imaging sequence; selecting at least one objective function from a plurality of objective functions; selecting an acquisition train length; selecting a k-space strategy; selecting one or more imaging parameters; and acquiring a magnetic resonance (MR) image using at least one of an optimized k-space strategy, an optimized acquisition train length, or optimized imaging parameters.

Abstract: Provided herein is a composition and a method for treating nucleic acid-related eye disease.

Abstract: Isolated polypeptides with lipase activity; polynucleotides encoding the polypeptides; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the polypeptides for cleaning are disclosed.

Abstract: Disclosed is a formulation of the following enzymes: Beta Glucanase, Chymotrypsin, Phytase, Lactase, and Invertase, which has been found to be effective in treating salicylate intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: acid reflux disease, stuttering, migraines, ADHD, behavioral deficits, Tourettes disease, seizures, autism (ASD), atrial fibrillation, anxiety, depression, joint pain, cognitive and perceptual disorders, respiratory difficulties and non-diabetic neuropathy. The formulation is also for treating or reducing intolerance of gluten, corn or soy.

Abstract: The present disclosure provides a delivery system comprising (i) a physiologically acceptable carrier and (ii) a proteolytic enzyme or effector thereof for use in a method for relaxing fibers within a subject's oral cavity. In some embodiments, the relaxation is for use in tooth manipulation (particularly repositioning). In some embodiments, the method involves the use of the proteolytic enzyme or effector thereof at a concentration effective to cause relaxation of fibers between the tooth's alveolar bone and gingiva while maintaining integrity of the fibers surrounding the tooth. Also disclosed herein are methods for fiber relaxation and/or repositioning of tooth making use of the proteolytic enzyme or effector thereof.

Abstract: The present document describes an enzyme formulation comprising an enzyme mixture comprising from about 5% to about 45% (wt/wt) of a fungal protease enzyme; and from about 1.5% to about 50% (wt/wt) of at least one polysaccharide digesting enzyme; in combination with an acceptable pharmaceutical carrier. The present document also describes the use of the formulation of the present invention for the prevention or treatment of digestive disorder.

Abstract: A composition used in targeted mutagenesis is provided, which includes a first expression cassette comprising a nucleotide sequence which encodes a CAS9 endonuclease; a second expression cassette comprising a nucleotide sequence which encodes a guide RNA sequence, wherein the guide RNA sequence is complementary to a target genome nucleotide sequence in a cell; and a third expression cassette comprising a nucleotide sequence which encodes a Trex2 exonuclease (Trex2) gene. The first, second, and third expression cassettes may be a part or a portion of one or more expression vectors.

Abstract: The invention relates to the discovery that collagenase injections are effective in dissolving and lysing the collagenase septa network in the skin that comprises cellulite. As such, the invention relates to methods of treating cellulite in a patient in need of such treatment comprising injecting or otherwise delivering the effective amount of purified collagenase to the collagenase septa network of cellulite in the skin. The invention also relates to the use of collagenase in the manufacture of a medicament to treat cellulite of the skin.

Abstract: The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, homologs of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.

Abstract: The present invention relates to compositions and their uses, specifically provides supplements for equines, in particular horses and ponies. Such a composition is ideal for horses and ponies where encouraging a more energetic performance is required.

Abstract: Disclosed herein are compositions for inactivating the human CCR5 gene comprising engineered LAGLIDADG homing endonucleases (LHEs) and their derivatives, particularly derived from members of the \-Onul subfamily of LHE. Polynucleotides encoding such endonucleases, vectors comprising said polynucleotides, cells comprising or having been treated with such endonucleases, and therapeutic compositions deriving therefrom are also provided.

Abstract: The present inventors have shown that electroporation with calcium ions are efficient on cutaneous and subcutaneous nodules. In particular the present inventors here disclose that a solution comprising calcium ions (Ca2+) with a concentration of at least 0.1 M is extremely useful in a method of treating a neoplasm, such as cancer with means for causing transient permeabilization of the cell membranes of at least part of the neoplasm before, during and/or after administration of said solution, wherein said solution is administered with a ratio of 0.2 to 0.8 of the volume of said part of the neoplasm.

Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.

Abstract: Fragrance control is provided by articles of manufacture including various solid state fragrancing objects, methods of using such objects, and systems that employ one or more such objects. The solid state fragrancing object can be used to inconspicuously provide fragrance to a user in an environment by disposing the solid state fragrancing object in the environment and configuring the solid state fragrancing object as at least a portion of a fixture within the environment. The fragrancing object can be easy to manufacture, long lasting, provide fragrance that is consistently released over time, provide an indication to the user that the object needs to be replaced, and can hold a desired ratio of fragrance.

Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

Abstract: The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 1 1038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage.

Abstract: Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.

Abstract: The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein.

Abstract: A process for the endogenic catabolism of homocysteine and the control of homocysteine levels for treating disease and the degenerative diseases of aging is provided along with pharmaceutical compositions having thioretinamide, retinol or combinations thereof in combination with an enzyme or a pro-enzyme. The process includes the catabolism of homocysteine thiolactone in cells and tissues by catalyzing the reaction of homocysteine thiolactone with an enzyme-bound retinoic acid to increase the bioavailability of thioretinamide in diseased and aged cells and tissue.